基于石墨烯生物传感器的场效应生物传感检测蛋白质-蛋白质相互作用

Executive Industry Relevance

Field-effect biosensing using graphene transistors enables label-free, real-time detection of protein-protein interactions, supporting early-stage target validation in drug discovery. By quantifying binding affinity through electrical readouts, the method provides predictive confidence for therapeutic hypothesis de-risking. This approach addresses the need for reproducible, quantitative assays in preclinical target engagement studies.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses by measuring binding kinetics between target proteins like Hsp90 and client proteins such as Cdc37.
• Operational Value: Provides quantitative I-response data that supports functional target validation and pathway clarification.
• Predictive Value: Generates dose-dependent binding curves to inform lead identification and portfolio triage decisions.

Screening & Assay Development

• Assay Readiness: Produces standardized, regenerable sensor surfaces suitable for screening compound effects on protein interactions.
• Quantitative Output: Delivers concentration-dependent electrical signals enabling KD determination and hit confirmation.
• Platform Reuse: Supports repeated cycles of association, dissociation, and regeneration for scalable assay implementation.

Translational & Preclinical Research

• Translational Continuity: Bridges discovery-phase interaction data with preclinical models by validating target engagement in disease-relevant systems.
• Mechanistic De-risking: Clarifies Hsp90-Cdc37 interaction dynamics, reducing uncertainty in downstream biomarker and efficacy studies.
• Risk-Adjusted Advancement: Informs go/no-go decisions based on reproducible binding affinity measurements.

Pipeline & Workflow Integration

The method fits within the discovery continuum from target validation through lead optimization, enabling iterative assessment of molecular interactions that influence compound selection.

• Discovery Biology: Supports hypothesis testing by detecting and quantifying specific protein-protein interactions in controlled buffer conditions.
• Screening: Delivers reproducible, label-free readouts that facilitate compound screening against PPI targets.
• Analytics: Generates real-time current response (I-response) measurements that quantify binding affinity and kinetics.
• Translational Research: Connects molecular interaction data to preclinical continuity by confirming target engagement in physiologically relevant contexts.
• Enterprise Reuse: Establishes a regenerable biosensor platform applicable across multiple target classes and projects.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in target validation through direct, quantitative measurement of binding events.
• Operational Value: Ensures assay standardization and reproducibility via immobilized protein surfaces and regeneration cycles.
• Strategic Value: Improves capital efficiency by reducing late-stage failure risk through early mechanistic de-risking.
• Portfolio Impact: Enables risk-adjusted prioritization of targets based on validated interaction strength and druggability.

Implementation Considerations

• Requires expertise in protein chemistry, surface functionalization, and electrochemical measurement techniques.
• Depends on access to graphene field-effect transistor instrumentation and fluidic control systems.
• Necessitates standardization of immobilization, quenching, and regeneration protocols across teams.
• Involves adaptation considerations for different protein pairs, buffer conditions, and analyte solubility profiles.
• Includes practical limitations such as surface fouling over cycles and the need for optimized surface density to avoid mass transport effects.

Biopharma FAQs